ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) Stock Now Rated “Hold” by Sell-Side Analysts

07 Nov 2026, 05:19 by Jessica Moore · The Cerbat Gem

ANI Pharmaceuticals, Inc. (NASDAQ:ANIP – Get Free Report) has received a consensus recommendation of “Hold” from the seven brokerages that are covering the firm, Marketbeat Ratings reports. Four research analysts have rated the stock with a hold recommendation and three have issued a buy recommendation on the company. The average twelve-month price target among brokers that have covered the stock in the last year is $100.00.

Several equities research analysts have recently issued reports on ANIP shares. Wall Street Zen lowered shares of ANI Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research note on Saturday, August 8th. Canaccord Genuity Group cut their target price on shares of ANI Pharmaceuticals from $91.00 to $90.00 and set a “hold” rating on the stock in a report on Monday, August 10th. Oppenheimer began coverage on shares of ANI Pharmaceuticals in a research report on Wednesday, September 23rd. They issued a “market perform” rating and a $85.00 price objective for the company. Weiss Ratings cut ANI Pharmaceuticals from a “buy (b-)” rating to a “hold (c+)” rating in a research note on Tuesday, August 11th. Finally, Guggenheim raised their price target on ANI Pharmaceuticals from $119.00 to $121.00 and gave the company a “buy” rating in a report on Friday.

Read Our Latest Report on ANIP

Key ANI Pharmaceuticals News

Here are the key news stories impacting ANI Pharmaceuticals this week:

Positive Sentiment: ANI reported Q3 2026 adjusted earnings of $2.70 per share, above the roughly $2.18 analyst consensus, and revenue of $290.78 million versus estimates of $280.59 million. Revenue grew 27.6% year over year, supporting the company’s growth outlook. ANI Q3 financial results
Positive Sentiment: Guggenheim raised its price target from $119 to $121 and maintained a Buy rating, signaling continued analyst confidence in ANIP’s prospects. Guggenheim ratings
Neutral Sentiment: ANI announced a recommended offer to acquire Swedish biotech Egetis Therapeutics for SEK 5.6 billion (about $560 million). The deal would expand ANI’s rare-disease business, but its financial impact and execution will matter to investors. ANI offer for Egetis
Negative Sentiment: The sizable acquisition may raise concerns about funding, integration, and the risks of expanding into a new business, potentially weighing on shares despite the earnings beat. ANI offer to acquire Egetis

ANI Pharmaceuticals Stock Down 3.2%

Shares of ANI Pharmaceuticals stock opened at $67.41 on Monday. The company has a 50-day simple moving average of $72.52 and a two-hundred day simple moving average of $77.32. The stock has a market capitalization of $1.55 billion, a PE ratio of 13.43, a price-to-earnings-growth ratio of 2.28 and a beta of 0.45. The company has a debt-to-equity ratio of 0.99, a quick ratio of 2.41 and a current ratio of 2.91. ANI Pharmaceuticals has a 52-week low of $67.14 and a 52-week high of $95.45.

ANI Pharmaceuticals (NASDAQ:ANIP – Get Free Report) last announced its quarterly earnings data on Thursday, November 5th. The specialty pharmaceutical company reported $2.70 EPS for the quarter, beating analysts’ consensus estimates of $2.18 by $0.52. ANI Pharmaceuticals had a net margin of 11.07% and a return on equity of 27.37%. The firm had revenue of $290.78 million during the quarter, compared to the consensus estimate of $280.59 million. During the same quarter last year, the firm earned $2.04 earnings per share. The firm’s revenue was up 27.6% compared to the same quarter last year. On average, analysts anticipate that ANI Pharmaceuticals will post 7.76 EPS for the current fiscal year.

Insider Activity at ANI Pharmaceuticals

In related news, Director Jeanne Thoma sold 1,000 shares of the company’s stock in a transaction dated Friday, September 11th. The stock was sold at an average price of $71.53, for a total value of $71,530.00. Following the completion of the sale, the director owned 26,762 shares in the company, valued at approximately $1,914,285.86. This represents a 3.60% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Nikhil Lalwani sold 5,400 shares of the stock in a transaction dated Thursday, October 15th. The shares were sold at an average price of $71.89, for a total value of $388,206.00. Following the completion of the transaction, the chief executive officer owned 333,689 shares of the company’s stock, valued at $23,988,902.21. This represents a 1.59% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 30,412 shares of company stock worth $2,220,970 in the last three months. Corporate insiders own 8.10% of the company’s stock.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently made changes to their positions in the business. Aberdeen Group plc boosted its position in shares of ANI Pharmaceuticals by 23.0% in the third quarter. Aberdeen Group plc now owns 334,350 shares of the specialty pharmaceutical company’s stock worth $24,291,000 after buying an additional 62,590 shares during the period. Eurizon Capital SGR S.p.A. acquired a new position in shares of ANI Pharmaceuticals in the 3rd quarter valued at $32,000. Maryland State Retirement & Pension System lifted its stake in ANI Pharmaceuticals by 66.4% in the 3rd quarter. Maryland State Retirement & Pension System now owns 4,430 shares of the specialty pharmaceutical company’s stock valued at $322,000 after purchasing an additional 1,768 shares during the last quarter. Illinois Municipal Retirement Fund boosted its stake in ANI Pharmaceuticals by 7.2% in the third quarter. Illinois Municipal Retirement Fund now owns 9,719 shares of the specialty pharmaceutical company’s stock valued at $706,000 after buying an additional 651 shares in the last quarter. Finally, Penn Capital Management Company LLC increased its holdings in ANI Pharmaceuticals by 2.8% in the third quarter. Penn Capital Management Company LLC now owns 213,246 shares of the specialty pharmaceutical company’s stock worth $15,515,000 after purchasing an additional 5,884 shares in the last quarter. 76.05% of the stock is owned by institutional investors and hedge funds.

About ANI Pharmaceuticals

(Get Free Report)

ANI Pharmaceuticals, Inc is a specialty pharmaceutical company that develops, manufactures and markets branded and generic prescription medicines. The company focuses on products with limited competition, complex formulations and specialized manufacturing requirements, serving therapeutic areas that include endocrinology, immunology, ophthalmology, dermatology and central nervous system disorders.